Results 21 to 30 of about 352,925 (341)

Doxorubicin Cardiomyopathy [PDF]

Cardiology, 2009
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained.
Kanu, Chatterjee, Jianqing, Zhang, Norman, Honbo, Joel S, Karliner   +3 more
openaire   +2 more sources

Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity

JACC. CardioOncology, 2020
Objectives: This study investigated the cardioprotective effect of repeated remote ischemic preconditioning (rRIC) on doxorubicin-induced cardiotoxicity in mice.
Quan He, PhD, Fangfei Wang, MD, Thomas D. Ryan, PhD, MD, Meghana Chalasani, BS, Andrew N. Redington, MD   +4 more
doaj   +1 more source

Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Biomolecules, 2022
Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.
Wang Yin, Cuong V. Pham, Tao Wang, Hadi Al Shamaileh, Rocky Chowdhury, Shweta Patel, Yong Li, Lingxue Kong, Yingchu Hou, Yimin Zhu, Sunrui Chen, Huo Xu, Lee Jia, Wei Duan, Dongxi Xiang   +14 more
doaj   +1 more source

Zymosan A Improved Doxorubicin‐Induced Ventricular Remodeling by Evoking Heightened Cardiac Inflammatory Responses and Healing in Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Doxorubicin‐induced myocardial injury is reflected by the presence of vacuolization in both clinical and animal models. The lack of scar tissue to replace the vacuolizated cardiomyocytes indicates that insufficient cardiac inflammation and ...
Guiwen Xu, Zhujing Hao, Wei Xiao, Ruopeng Tan, Mengyang Yuan, Yunlong Xia, Yang Liu   +6 more
doaj   +1 more source

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling

Acta Pharmaceutica Sinica B, 2023
Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein,
Kezheng Peng, Chenye Zeng, Yuqi Gao, Binliang Liu, Liyuan Li, Kang Xu, Yuemiao Yin, Ying Qiu, Mingkui Zhang, Fei Ma, Zhao Wang   +10 more
doaj   +1 more source

Decreased soluble guanylate cyclase contributes to cardiac dysfunction induced by chronic doxorubicin treatment in mice [PDF]

, 2017
Aims: The use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of doxorubicin-induced cardiotoxicity ...
Allen, Kaitlin, Bartunek, Jozef, Beerens, Manu, Bloch, Donald B, Bloch, Kenneth D, Brouckaert, Peter, Buys, Emmanuel S, Caluwe, Ellen, Gillijns, Hilde, Janssens, Stefan P, Nathan, Daniel I, Scherrer-Crosbie, Marielle, Swinnen, Melissa, Tainsh, Robert E, Vandenwijngaert, Sara, Walravens, Ann-Sophie   +15 more
core   +1 more source

A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity.

PLoS Computational Biology, 2011
Although doxorubicin toxicity in cancer cells is multifactorial, the enzymatic bioactivation of the drug can significantly contribute to its cytotoxicity. Previous research has identified most of the components that comprise the doxorubicin bioactivation
Nnenna A Finn, Harry W Findley, Melissa L Kemp   +2 more
doaj   +1 more source

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin [PDF]

, 2018
Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection.
Abrar, Mohammed Burhan, Abuosa, Ahmed Mohamed, Ahmed, Adel H., Andejani, Abdulwahab, Cleland, John G.F., Elshiekh, Ayman Hassan, Kholeif, Mona A., Kinsara, Abdulhalim Jamal, Qureshi, Kahekashan   +8 more
core   +1 more source

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC Cancer, 2018
Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes.
William P. McGuire, Richard T. Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria   +6 more
doaj   +1 more source

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis

Current Problems in Cancer: Case Reports, 2020
Drug induced pancreatitis is rare and establishing the exact causal relationship is challenging. Here, we discuss the management of a 60 year-old female patient with stage 3a breast cancer who developed doxorubicin induced pancreatitis 3 days after her ...
Luke Ardolino, Eugene Moylan
doaj   +1 more source